PMC:7361216 / 4423-4937 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T56","span":{"begin":32,"end":35},"obj":"Body_part"},{"id":"T57","span":{"begin":104,"end":107},"obj":"Body_part"},{"id":"T58","span":{"begin":108,"end":116},"obj":"Body_part"},{"id":"T59","span":{"begin":151,"end":156},"obj":"Body_part"},{"id":"T60","span":{"begin":224,"end":227},"obj":"Body_part"},{"id":"T61","span":{"begin":238,"end":246},"obj":"Body_part"},{"id":"T62","span":{"begin":414,"end":417},"obj":"Body_part"}],"attributes":[{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma62873"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T12","span":{"begin":36,"end":57},"obj":"Disease"}],"attributes":[{"id":"A12","pred":"mondo_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/MONDO_0004960"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T65","span":{"begin":149,"end":156},"obj":"http://purl.obolibrary.org/obo/CL_0000236"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T37","span":{"begin":377,"end":384},"obj":"Chemical"},{"id":"T38","span":{"begin":471,"end":478},"obj":"Chemical"}],"attributes":[{"id":"A37","pred":"chebi_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"},{"id":"A38","pred":"chebi_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_59132"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T17","span":{"begin":151,"end":156},"obj":"http://purl.obolibrary.org/obo/CL_0000000"},{"id":"T18","span":{"begin":195,"end":202},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"},{"id":"T19","span":{"begin":403,"end":413},"obj":"http://purl.obolibrary.org/obo/IDO_0000450"},{"id":"T20","span":{"begin":426,"end":433},"obj":"http://purl.obolibrary.org/obo/OGMS_0000031"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T32","span":{"begin":352,"end":357},"obj":"Chemical"}],"attributes":[{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_137080"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T27","span":{"begin":0,"end":172},"obj":"Sentence"},{"id":"T28","span":{"begin":173,"end":324},"obj":"Sentence"},{"id":"T29","span":{"begin":325,"end":434},"obj":"Sentence"},{"id":"T30","span":{"begin":435,"end":514},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"122","span":{"begin":3,"end":11},"obj":"Species"},{"id":"123","span":{"begin":162,"end":171},"obj":"Chemical"},{"id":"121","span":{"begin":257,"end":260},"obj":"Gene"},{"id":"124","span":{"begin":288,"end":297},"obj":"Chemical"},{"id":"125","span":{"begin":352,"end":357},"obj":"Chemical"}],"attributes":[{"id":"A124","pred":"pubann:denotes","subj":"124","obj":"MESH:D000069283"},{"id":"A122","pred":"pubann:denotes","subj":"122","obj":"Tax:9606"},{"id":"A123","pred":"pubann:denotes","subj":"123","obj":"MESH:D000069283"},{"id":"A121","pred":"pubann:denotes","subj":"121","obj":"Gene:4099"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T50","span":{"begin":144,"end":148},"obj":"Protein"},{"id":"T57","span":{"begin":257,"end":260},"obj":"Protein"}],"attributes":[{"id":"A50","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/Q3C2E2"},{"id":"A51","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/Q13963"},{"id":"A52","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/P19437"},{"id":"A53","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/P11836"},{"id":"A54","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/P08984"},{"id":"A55","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/B4DT24"},{"id":"A56","pred":"uniprot_id","subj":"T50","obj":"https://www.uniprot.org/uniprot/A6NMS4"},{"id":"A57","pred":"uniprot_id","subj":"T57","obj":"https://www.uniprot.org/uniprot/Q567S4"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T56","span":{"begin":32,"end":35},"obj":"Body_part"},{"id":"T57","span":{"begin":104,"end":107},"obj":"Body_part"},{"id":"T58","span":{"begin":108,"end":116},"obj":"Body_part"},{"id":"T59","span":{"begin":151,"end":156},"obj":"Body_part"},{"id":"T60","span":{"begin":224,"end":227},"obj":"Body_part"},{"id":"T61","span":{"begin":238,"end":246},"obj":"Body_part"},{"id":"T62","span":{"begin":414,"end":417},"obj":"Body_part"}],"attributes":[{"id":"A59","pred":"fma_id","subj":"T59","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A57","pred":"fma_id","subj":"T57","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A62","pred":"fma_id","subj":"T62","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A58","pred":"fma_id","subj":"T58","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A56","pred":"fma_id","subj":"T56","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A60","pred":"fma_id","subj":"T60","obj":"http://purl.org/sig/ont/fma/fma62873"},{"id":"A61","pred":"fma_id","subj":"T61","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T15","span":{"begin":36,"end":57},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0004960"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sample-PD-HP","denotations":[{"id":"T5","span":{"begin":214,"end":234},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0003496"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T5","span":{"begin":214,"end":234},"obj":"Phenotype"}],"attributes":[{"id":"A5","pred":"hp_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/HP_0003496"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T27","span":{"begin":0,"end":172},"obj":"Sentence"},{"id":"T28","span":{"begin":173,"end":324},"obj":"Sentence"},{"id":"T29","span":{"begin":325,"end":434},"obj":"Sentence"},{"id":"T30","span":{"begin":435,"end":514},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"121","span":{"begin":257,"end":260},"obj":"Gene"},{"id":"122","span":{"begin":3,"end":11},"obj":"Species"},{"id":"123","span":{"begin":162,"end":171},"obj":"Chemical"},{"id":"124","span":{"begin":288,"end":297},"obj":"Chemical"},{"id":"125","span":{"begin":352,"end":357},"obj":"Chemical"}],"attributes":[{"id":"A121","pred":"tao:has_database_id","subj":"121","obj":"Gene:4099"},{"id":"A122","pred":"tao:has_database_id","subj":"122","obj":"Tax:9606"},{"id":"A123","pred":"tao:has_database_id","subj":"123","obj":"MESH:D000069283"},{"id":"A124","pred":"tao:has_database_id","subj":"124","obj":"MESH:D000069283"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In patients suffering from this IgM monoclonal gammopathy, non‐specific strategies are used to diminish IgM antibody including targeting of all CD20 B cells with Rituximab. On occasion flares of disease occur with increased IgM levels of antibody targeting MAG have followed therapy with Rituximab (Broglio and Luria, 2005). The strategy employed with PPSGG is specific to the antigen that triggers the pathogenic IgM in this disease. One can refer to such treatment as “antigen‐specific” immunotherapy (Figure 1)."}